APA (7th ed.) Citation

Basso, U., Paolieri, F., Porta, C., De Giorgi, U., Bracarda, S., Antonuzzo, L., . . . Tortora, G. (2020). 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study. Annals of Oncology, 31, S566. https://doi.org/10.1016/j.annonc.2020.08.793

Chicago Style (17th ed.) Citation

Basso, U., et al. "721P Ipilimumab and Nivolumab Compassionate Use Program in Metastatic Renal Cell Carcinoma Patients with Intermediate or Poor IMDC Risk Score: The Large Multicenter Italian Study." Annals of Oncology 31 (2020): S566. https://doi.org/10.1016/j.annonc.2020.08.793.

MLA (9th ed.) Citation

Basso, U., et al. "721P Ipilimumab and Nivolumab Compassionate Use Program in Metastatic Renal Cell Carcinoma Patients with Intermediate or Poor IMDC Risk Score: The Large Multicenter Italian Study." Annals of Oncology, vol. 31, 2020, p. S566, https://doi.org/10.1016/j.annonc.2020.08.793.